Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults (original) (raw)

Journal Article

,

1

Department of Medicine, Emory University School of Medicine

,

Atlanta, Georgia

Reprints or correspondence: Dr. Frances H. Priddy, The Hope Clinic of the Emory Vaccine Ctr., Emory University, 603 Church St., Decatur, GA 30030 (fpriddy@emory.edu).

Search for other works by this author on:

,

2

Merck Research Laboratories

,

West Point, Pennsylvania

Search for other works by this author on:

,

3

Fred Hutchinson Cancer Research Center

,

Seattle, Washington

Search for other works by this author on:

,

2

Merck Research Laboratories

,

West Point, Pennsylvania

Search for other works by this author on:

,

4

Central Texas Clinical Research Center

,

Austin

Search for other works by this author on:

,

5

Quest Clinical Research Laboratories

,

San Francisco

Search for other works by this author on:

,

7

Care Resource

,

Miami, Florida

Search for other works by this author on:

,

8

New York University School of Medicine

,

New York

Search for other works by this author on:

,

9

Warren Alpert Medical School of Brown University

,

Providence, Rhode Island

Search for other works by this author on:

,

10

University of Illinois at Chicago

,

Chicago

Search for other works by this author on:

... Show more

Received:

19 November 2007

Accepted:

18 January 2008

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Frances H. Priddy, Deborah Brown, James Kublin, Kathleen Monahan, David P. Wright, Jacob Lalezari, Steven Santiago, Michael Marmor, Michelle Lally, Richard M. Novak, Stephen J. Brown, Priya Kulkarni, Sheri A. Dubey, Lisa S. Kierstead, Danilo R. Casimiro, Robin Mogg, Mark J. DiNubile, John W. Shiver, Randi Y. Leavitt, Michael N. Robertson, Devan V. Mehrotra, Erin Quirk, Merck V520-016 Study Group, Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults, Clinical Infectious Diseases, Volume 46, Issue 11, 1 June 2008, Pages 1769–1781, https://doi.org/10.1086/587993
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Background. The safety and immunogenicity of the MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine, a replication-incompetent adenovirus type 5—vectored vaccine designed to elicit cell-mediated immunity against conserved human immunodeficiency virus proteins, was assessed in a phase 1 trial.

Methods. Healthy adults not infected with human immunodeficiency virus were enrolled in a multicenter, dose-escalating, blind, placebo-controlled study to evaluate a 3-dose homologous prime-boost regimen of the trivalent MRK adenovirus type 5 human immunodeficiency virus type 1 vaccine containing from 3×106 to 1×1011 viral particles per 1-mL dose administered on day 1, during week 4 and during week 26. Adverse events were recorded for 29 days after each intradeltoid injection. The primary immunogenicity end point was the proportion of study participants with a positive unfractionated Gag-, Pol-, or Nef-specific interferon-γ enzyme-linked immunosorbent spot response measured 4 weeks after administration of the last dose.

Results. Of 259 randomized individuals, 257 (99%) received ⩾1 dose of vaccine or placebo and were included in the safety analyses. Enzyme-linked immunosorbent spot results were available for 217 study participants (84%) at week 30. No serious vaccine-related adverse events occurred. No study participant discontinued participation because of vaccine-related adverse events. The frequency of injection-site reactions was dose dependent. Vaccine doses of ⩾3×109 viral particles elicited positive enzyme-linked immunosorbent spot responses to ⩾1 vaccine component in >60% of recipients. High baseline antibody titers against adenovirus type 5 diminished enzyme-linked immunosorbent spot responses at all doses except the 3×1010 viral particle dose.

Conclusions. The vaccine was generally well tolerated and induced cell-mediated immune responses against human immunodeficiency virus type 1 peptides in most healthy adults. Despite these findings, vaccination in a proof-of-concept trial with use of this vaccine was discontinued because of lack of efficacy.

© 2008 by the Infectious Diseases Society of America

Topic:

• hiv
• adenoviruses
• adult
• hiv-1
• safety
• vaccines
• virion
• hiv clade b
• adverse event

You do not currently have access to this article.

I agree to the terms and conditions. You must accept the terms and conditions.

Submit a comment

Name

Affiliations

Comment title

Comment

You have entered an invalid code

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults - 24 Hours access

EUR €38.00

GBP £33.00

USD $41.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 3,198

2,328 Pageviews

870 PDF Downloads

Since 12/1/2016

Citations

192 Web of Science

×

Email alerts

More on this topic

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic